1. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA.
2021;326:851–62.
2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J
Med. 2011;364:1817–25.
3. Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al.
Effect of chemoradiotherapy vs chemotherapy on survival in patients with
locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA.
2016;315(17):1844–53.
4. Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, et al. Focal radiation
therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative
chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94:755–65.
5. Reyngold M, O’Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, Romesser
PB, et al. Association of ablative radiation therapy with survival among
patients with inoperable pancreatic cancer. JAMA Oncol. 2021;7:735–8.
6. Courtney PT, Paravati AJ, Atwood TF, Raja N, Zimmerman CT, Fanta PT, et al.
Phase I trial of stereotactic body radiation therapy dose escalation in pancreatic cancer. Int J Radiat Oncol Biol Phys. 2021;110:1003–12.
7. Goto Y, Nakamura A, Ashida R, Sakanaka K, Itasaka S, Shibuya K, et al. Clinical
evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiat Oncol. 2018;13:118.
8. Niedzielski JS, Liu Y, Ng SSW, Martin RM, Perles LA, Beddar S, et al. Dosimetric uncertainties resulting from interfractional anatomic variations for
patients receiving pancreas stereotactic body radiation therapy and cone
beam computed tomography image guidance. Int J Radiat Oncol Biol Phys.
2021;111:1298–309.
9. Henke L, Kashani R, Yang D, Zhao T, Green O, Olsen L, et al. Simulated online
adaptive magnetic resonance-guided stereotactic body radiation therapy
for the treatment of oligometastatic disease of the abdomen and central
thorax: characterization of potential advantages. Int J Radiat Oncol Biol Phys.
2016;96:1078–86.
10. Engels B, Soete G, Verellen D, Storme G. Conformal arc radiotherapy for
prostate cancer: increased biochemical failure in patients with distended
rectum on the planning computed tomogram despite image guidance by
implanted markers. Int J Radiat Oncol Biol Phys. 2009;74:388–91.
11. Nakamura A, Shibuya K, Nakamura M, Matsuo Y, Shiinoki T, Nakata M, et al.
Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer: implications for
a dose-escalation strategy. Med Phys. 2013;40:021701.
12. Iwai T, Yoshimura M, Ashida R, Goto Y, Kishi T, Itasaka S, et al. Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for
18. 19. 20. 21. 22. 23. 24. 25. 26. elderly patients with locally advanced pancreatic carcinoma. Radiat Oncol.
2020;15:264.
Sasaki M, Nakamura M, Ono T, Ashida R, Yoshimura M, Nakata M, et al.
Positional repeatability and variation in internal and external markers during
volumetric-modulated arc therapy under end-exhalation breath-hold conditions for pancreatic cancer patients. J Radiat Res. 2020;61:755–65.
Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet.
2009;374:1449–61.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for
medical statistics. Bone Marrow Transplant. 2013;48:452–8.
Nakamura A, Shibuya K, Matsuo Y, Nakamura M, Shiinoki T, Mizowaki T, et
al. Analysis of dosimetric parameters associated with acute gastrointestinal
toxicity and upper gastrointestinal bleeding in locally advanced pancreatic
cancer patients treated with gemcitabine-based concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:369–75.
Bittner M-I, Grosu A-L, Brunner TB. Comparison of toxicity after IMRT and
3D-conformal radiotherapy for patients with pancreatic cancer - a systematic
review. Radiother Oncol. 2015;114:117–21.
Goldsmith C, Price P, Cross T, Loughlin S, Cowley I, Plowman N. Dose-volume
histogram analysis of stereotactic body radiotherapy treatment of pancreatic cancer: a focus on duodenal dose constraints. Semin Radiat Oncol.
2016;26:149–56.
Cattaneo GM, Passoni P, Longobardi B, Slim N, Reni M, Cereda S, et al. Dosimetric and clinical predictors of toxicity following combined chemotherapy
and moderately hypofractionated rotational radiotherapy of locally advanced
pancreatic adenocarcinoma. Radiother Oncol. 2013;108:66–71.
Alam S, Veeraraghavan H, Tringale K, Amoateng E, Subashi E, Wu AJ, et al.
Inter- and intrafraction motion assessment and accumulated dose quantification of upper gastrointestinal organs during magnetic resonance-guided
ablative radiation therapy of pancreas patients. Phys Imaging Radiat Oncol.
2022;21:54–61.
Ogawa A, Nakamura M, Iramina H, Yoshimura M, Mizowaki T. Potential utility
of cone-beam CT-guided adaptive radiotherapy under end-exhalation
breath-hold conditions for pancreatic cancer. J Appl Clin Med Phys.
2022;24:e13827.
Reyngold M, Parikh P, Crane CH. Ablative radiation therapy for locally
advanced pancreatic cancer: techniques and results. Radiat Oncol.
2019;14:95.
Hassanzadeh C, Rudra S, Bommireddy A, Hawkins WG, Wang-Gillam A,
Fields RC, et al. Ablative five-fraction stereotactic body radiation therapy for
inoperable pancreatic cancer using online MR-guided adaptation. Adv Radiat
Oncol. 2021;6:100506.
Chuong MD, Bryant J, Mittauer KE, Hall M, Kotecha R, Alvarez D, et al. Ablative
5-fraction stereotactic magnetic resonance-guided radiation therapy with
on-table adaptive replanning and elective nodal irradiation for inoperable
pancreas cancer. Pract Radiat Oncol. 2021;11:134–47.
Gardner SJ, Mao W, Liu C, Aref I, Elshaikh M, Lee JK, et al. Improvements in
CBCT image quality using a novel iterative reconstruction algorithm: a clinical
evaluation. Adv Radiat Oncol. 2019;4:390–400.
Schiff JP, Stowe HB, Price A, Laugeman E, Hatscher C, Hugo GD, et al. In silico
trial of computed tomography-guided stereotactic adaptive radiotherapy
(CT-STAR) for the treatment of abdominal oligometastases. Int J Radiat Oncol
Biol Phys. 2022;114:1022–31.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
...
論文の公開元へ
